Posted by Michael Wonder on 26 Jun 2026
Celecor completes submission of FDA new drug application for investigational heart attack drig
24 June 2026 - CeleCor Therapeutics has submitted the final section of its new drug application for the company's investigational heart-attack drug, zalunfiban (Disaggpro), to the US FDA.
The new drug application filing follows presentation in November of positive Phase 3 results from its CeleBrate study at the American Heart Association Scientific Sessions, as well as publication of the results in The New England Journal of Medicine Evidence.
